Scientific deep-dive
GLP-1s and Worsening Mental Illness
Semaglutide was associated with 42% lower risk of worsening mental illness in people with depression and anxiety. Exenatide and dulaglutide showed nothing. Four drugs, one class, two very different results.
A Swedish cohort followed people with depression and anxiety who took GLP-1 drugs, and found something more interesting than a simple answer. Semaglutide was associated with a 42% lower risk of worsening mental illness. Liraglutide was associated with an 18% lower risk, and exenatide and dulaglutide with none at all.[1]
What was found
| Drug | Worsening mental illness |
|---|---|
| Semaglutide | 0.58 (95% CI 0.51–0.65) |
| Liraglutide | 0.82 (95% CI 0.76–0.89) |
| Exenatide | 1.01 (95% CI 0.69–1.46) |
| Dulaglutide | 1.01 (95% CI 0.85–1.20) |
For semaglutide the effect appeared across all three specific outcomes: worsening depression at 0.56, worsening anxiety at 0.62, and worsening substance use disorder at 0.53. Liraglutide moved only depression, at 0.74. Across the class as a whole, self-harm was lower, at 0.56 (confidence interval 0.34 to 0.92).[1]
Why the split between drugs is the finding
We have now seen this shape twice. In a meta-analysis of atrial fibrillation, the class was neutral and the signal appeared specific to semaglutide, which we covered in reading a 42% headline. Here again, two drugs move and two do not. The wider record on suicidal thoughts and psychiatric safety is gathered in ten studies on GLP-1s and mental health.
An effect that lands on some members of a drug class and not others is either real pharmacology or a description of who receives which drug.
Both explanations are live. The design removes one large source of bias: it compares each person’s periods on a drug with their own periods off it, so stable differences between people cancel out.[1] It cannot remove everything. Each drug’s estimate comes only from the people who took it, and semaglutide, the newest and most effective of the four, reached different people than exenatide. Who reaches any of them is skewed as well: in diabetes, people with a mental health diagnosis have a quarter of the odds of being prescribed a GLP-1. Whatever changes around the time someone starts a drug, such as closer contact with their care, can also move a mental-health trajectory.
There is also a straightforward mediating route that has nothing to do with the brain: semaglutide produces far more weight loss than exenatide, and losing a great deal of weight changes mobility, sleep, pain and how people are treated by others. A drug that improves depression through those channels is still helping, but that is not evidence of a direct psychiatric mechanism.
The self-harm result, and where it sits
The class-wide self-harm finding matters because it speaks to the harm this drug class has been most publicly accused of. A hazard ratio of 0.56 points in the opposite direction from harm, in a population selected for existing depression and anxiety, the group in which any risk would show up first.
Set that against the spontaneous-reporting signal we covered in the FAERS analysis, which pointed the other way. These are not equally strong designs: a national cohort that compares each person with themselves beats voluntary reports with no denominator, and the regulatory picture is covered in what happened with the suicidality signal.
Frequently Asked Questions
References
- 1.Taipale H, Taylor M, Lähteenvuo M, et al. Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a nationwide cohort study The Lancet Psychiatry. 2026. PMID: 41862258.
Compare the sellers
Related research
GLP-1s and Antipsychotic Weight Gain: A Trial Cut Short
Semaglutide produced 13.88% weight loss against 0.42% on placebo in people taking clozapine, without altering clozapine levels or psychotic symptoms. The trial ended at 31 of an intended 80 because the drug ran out.
6 min read
Antidepressants and a GLP-1: Ozempic, Wellbutrin, Lexapro and What the Labels Say
No GLP-1 label names an antidepressant as an interaction, and people on antidepressants lost as much weight on semaglutide as everyone else. The real overlaps: stacked nausea, slowed absorption of tablets, and two bupropion rules.
11 min read
Tirzepatide Versus Semaglutide on Mood
Across more than 85,000 matched pairs over two years, psychiatric outcomes were the same for both drugs. Against older GLP-1s, semaglutide was associated with about half the hazard of suicidal ideation.
5 min read
Semaglutide and Motivation
Semaglutide reduced how heavily people with depression discounted effort, while leaving their sensitivity to probability unchanged. That dissociation is what makes the finding hard to dismiss.
5 min read
When the Primary Endpoint Fails and a Secondary Doesn't
A randomized trial in 72 people with major depressive disorder found no effect on executive function, its primary outcome. A secondary cognition measure cleared p=0.03, and that is the one that will be reported.
5 min read
Metformin and a GLP-1 Together: The Risk Is Not the One People Expect
The diabetes trials behind these drugs were largely run on people already taking metformin. Stomach side effects did not stack in the largest analysis, and low blood sugar comes from other drugs. The real overlap is dehydration.
8 min read
Where to get semaglutide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Embody
From $79/mo
Get started →Collective
From $59/mo + membership
Get started →MyDrHank
An oral route if you will not self-inject
From $249/mo
Get started →